COMMUNIQUÉS West-GlobeNewswire

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
22/10/2026
TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage [...]
Promaxo Announces Closing of Series C Financing and $100M Credit Facility
22/10/2026
The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings OAKLAND, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Promaxo today announced the initial close of its Series C [...]
Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
22/10/2026
Submission marks an important milestone towards bringing a new treatment option to patients with DMD in South Korea. Vamorolone has already received South Korean Orphan Drug Designation (ODD) and Global Innovative [...]
Levicept Announces Attendance at Major Healthcare Conferences in Q4
22/10/2026
SANDWICH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), is pleased to [...]
KFSH Expands Capacity for Complex Care by Redesigning the Emergency Patient Journey
22/10/2026
RIYADH, Saudi Arabia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has expanded capacity for complex care by redesigning the emergency patient journey, meeting rising [...]
Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection
22/10/2026
kt-5000AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection VANCOUVER, British [...]
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
22/10/2026
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, [...]
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
22/10/2026
LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30 [...]
Une nouvelle étude sur EggNest® publiée dans JAHA et une dérogation réglementaire au Texas confirment l’évolution vers des procédures sans tablier plombé en salle de cardiologie interventionnelle
22/10/2026
MINNEAPOLIS, 22 oct. 2026 (GLOBE NEWSWIRE) -- Egg Medical a annoncé aujourd’hui la publication d’une étude prospective dans le Journal of the American Heart Association (JAHA), évaluant ses dispositifs renforcés de [...]
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
22/10/2026
Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on track for submission [...]
Pharming Group announces third quarter 2026 revenues above market expectations
22/10/2026
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]
22/10/2026
Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% ( [...]
Ipsen réalise une croissance remarquable des ventes au cours des neuf premiers mois de 2026 et relève à nouveau ses prévisions pour l’exercice en cours
22/10/2026
Croissance du chiffre d’affaires du Groupe de 24,6 % à taux de change constant 1 (TCC) au cours des neuf premiers mois de l’année 2026 ou 23,0 % en données publiées, avec une croissance du portefeuille stratégique 2 de [...]
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
22/10/2026
Year-to-date total sales growth of 24.6% at CER 1 , or 23.0% as reported, with the core portfolio 2 achieving sales growth of 24.2% 1 Further upgraded FY 2026 financial guidance: total sales growth around 23.0% at CER ( [...]
Persica Pharmaceuticals presents antibiotic exposure-response analysis at the International Society of Pain & Neuroscience (ISPN) Annual Conference
22/10/2026
London, UK, 22 October 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today [...]
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
22/10/2026
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological [...]
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
22/10/2026
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological [...]
Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
22/10/2026
HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Asimov Announces Adoption of Its AI-Driven Cell Line Development Platform by LG Chem
22/10/2026
Asimov’s CHO Edge System, including the recently announced Chrysalis transposase and Kernel, Asimov’s AI-driven genetic design software, will support LG Chem’s biologics cell line development activities BOSTON, Oct. 21 [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum